大鼠脊髓损伤后椎管内注射重组腺病毒载体Ad5-VEGF与Ad5-ANG经星形胶质细胞介导的功能恢复
研究在大鼠脊髓损伤模型中将表达血管内皮生长因子(VEGF)和血管生成素(ANG)的重组腺病毒载体Ad5-VEGF+Ad5-ANG注入椎管内,观察到损伤后30天实验组Basso, Beattie, and Bresnahan(BBB)评分较对照组高35.9%,并伴GFAP+、S100β+、AQP4+细胞数量增加及S100β转录本2倍升高。作者认为该基因治疗可刺激创伤性脊髓损伤后的功能恢复,S100β+星形胶质细胞增多可能是维持神经元存活和功能的有益因素。
要点
- 大鼠脊髓损伤后椎管内注射Ad5-VEGF+Ad5-ANG,30天BBB评分较对照组高35.9%。
- 注射点头尾方向5 mm内可见GFP信号,损伤中心头尾5 mm内GFAP+、S100β+、AQP4+细胞增加1.5至2.0倍。
- 伤后30天实验组S100β转录本较对照组增加2倍,作者认为S100β+星形胶质细胞增多可能有益。
核心结论
- 椎管内注射编码VEGF和ANG的重组腺病毒载体可刺激创伤性脊髓损伤后的功能恢复。
- 该方法诱导的S100β+星形胶质细胞增多可能是维持神经元存活和功能的有益因素。
- 作者认为Ad5-VEGF+Ad5-ANG载体基因治疗是脊髓损伤治疗的有效方法。
研究设计与样本
- 成年Wistar大鼠采用重物坠落法诱导脊髓损伤,共51只分为实验组(Ad5-VEGF+Ad5-ANG)和对照组(Ad5-GFP)。
- 采用Basso, Beattie, and Bresnahan量表评估运动功能恢复。
- 通过免疫荧光检测GFP评估注射载体的感染性和基因表达持续时间与强度。
- 通过表达GFAP、S100β、水通道蛋白4(AQP4)、少突胶质细胞转录因子2和硫酸软骨素蛋白聚糖4的免疫阳性细胞数量变化评估胶质细胞反应性。
- 采用实时聚合酶链反应估计脊髓内S100β mRNA表达水平。
主要发现
- 术后30天两组均观察到部分运动功能恢复,但Ad5-VEGF+Ad5-ANG组Basso, Beattie, and Bresnahan评分较对照组高35.9%。
- 注射点头侧和尾侧方向最远5 mm处可见特异性GFP信号。
- 损伤中心头侧和尾侧方向最远5 mm处白质和灰质中GFAP+、S100β+和AQP4+细胞数量增加1.5至2.0倍。
- 伤后30天Ad5-VEGF+Ad5-ANG组S100β转录本较对照组增加2倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE The most actively explored therapeutic strategy for overcoming spinal cord injury (SCI) is the delivery of genes encoding molecules that stimulate regeneration. In a mouse model of amyotrophic lateral sclerosis and in preliminary clinical trials in patients with amyotrophic lateral sclerosis, the combined administration of recombinant adenoviral vectors (Ad5-VEGF+Ad5-ANG) encoding the neurotrophic/angiogenic factors vascular endothelial growth factor ( VEGF) and angiogenin ( ANG) was found to slow the development of neurological deficits. These results suggest that there may be positive effects of this combination of genes in posttraumatic spinal cord regeneration. The objective of the present study was to determine the effects of Ad5-VEGF+Ad5-ANG combination therapy on motor function recovery and reactivity of astrocytes in a rat model of SCI. METHODS Spinal cord injury was induced in adult Wistar rats by the weight-drop method. Rats (n = 51) were divided into 2 groups: the experimental group (Ad5-VEGF+Ad5-ANG) and the control group (Ad5-GFP [green fluorescent protein]). Recovery of motor function was assessed using the Basso, Beattie, and Bresnahan scale. The duration and intensity of infectivity and gene expression from the injected vectors were assessed by immunofluorescent detection of GFP. Reactivity of glial cells was assessed by changes in the number of immunopositive cells expressing glial fibrillary acidic protein (GFAP), S100β, aquaporin 4 (AQP4), oligodendrocyte transcription factor 2, and chondroitin sulfate proteoglycan 4. The level of S100β mRNA expression in the spinal cord was estimated by real-time polymerase chain reaction. RESULTS Partial recovery of motor function was observed 30 days after surgery in both groups. However, Basso, Beattie, and Bresnahan scores were 35.9% higher in the Ad5-VEGF+Ad5-ANG group compared with the control group. Specific GFP signal was observed at distances of up to 5 mm in the rostral and caudal directions from the points of injection. A 1.5 to 2.0-fold increase in the number of GFAP+, S100β+, and AQP4+ cells was observed in the white and gray matter at a distance of up to 5 mm from the center of the lesion site in the caudal and rostral directions. At 30 days after injury, a 2-fold increase in S100β transcripts was observed in the Ad5-VEGF+Ad5-ANG group compared with the control group. CONCLUSIONS Intraspinal injection of recombinant adenoviral vectors encoding VEGF and ANG stimulates functional recovery after traumatic SCI. The increased number of S100β+ astrocytes induced by this approach may be a beneficial factor for maintaining the survival and function of neurons. Therefore, gene therapy with Ad5-VEGF+Ad5-ANG vectors is an effective therapeutic method for SCI treatment.
引用
- Povysheva T, Shmarov M, Logunov D, et al. Post-spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG. J Neurosurg Spine. 2017. PMID: 28452633. doi:10.3171/2016.9.SPINE15959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。